Inclusion Criteria:  Documented history of stable angina (CCS grading I-III) or anginal equivalent for ≥1 month prior to screening Ability to safely abstain from beta blockers for 48 hours prior to echo examinations in the opinion of the Investigator Preserved LV systolic function, defined as LVEF≥50% by any imaging modality Obstructive CAD and recent evidence of stress-induced myocardial ischemia  Exclusion Criteria:  Women of childbearing potential or who are currently pregnant or breast-feeding Clinically indicated for coronary revascularization (PCI/CABG) at time of screening or clinically significant LMS or proximal LAD stenosis likely to warrant revascularization during the study period in the opinion of the investigator. Type 1 insulin dependent diabetes mellitus (IDDM) Presence of pacemaker, cardiac resynchronization therapy and/or implantable cardioverter defibrillator Severe or clinically significant valvular heart disease Clinically significant concurrent condition which could prevent the patient from performing any of the protocol-specified assessments, represent a safety concern if the patient participates in the trial or could confound trial assessments of safety or tolerability